Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma company to pair with the Crohn's and Colitis Foundation of America.
The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
Influential patients are reaching critical mass. What can't they do?
A study indicates consumers stop using them at the six-month mark.
The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.
NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."
He started the Dose of Digital blog in 2008, then left healthcare. Now, after more than two years away, Jonathan Richman says he's back in the business.
The FDA says the OTC remedy maker's online behavior—including Liking customer Facebook posts—has put the company's drugs in unapproved drug territory.
The drugmaker received a notice from the advertising watchdog over promotion of hep. B treatment Viread in a sponsored link on Google AdWords.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
The consumer-facing edition of The Merck Manual Go-To Home Guide for Symptoms is being released as a mobile app.
Researchers from Boston Children's Hospital, Harvard Medical School and Brigham and Women's Hospital are offering a bit of internet advice for the Food and Drug Administration: do more.
The networking site's emotion experiment rankles some in the science and political communities.
A US Pharma juror's—and silver Lions Health winner's—opinion on why the Americans didn't fare well in Cannes, and tips for improvement
Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.
GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.
Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect
Researchers are increasingly using social media to recruit patients, albeit oftentimes in an arms-length manner.
Guidance on promoting products in 140 characters and correcting misinformation serves as a guarded green light, says one observer.
Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.
FDA issued two guidance documents today for industry and its representatives to communicate online about prescription drugs and devices.
The Centers for Medicare and Medicaid Services launched a new site Monday to help patients understand how to use their health coverage.
Recent FDA guidelines for health-tracking apps mean Apple's HealthKit, and similar apps, won't have to jump regulatory hurdles before going live.
The health and lifestyle resource's latest app seeks to provide context for all that biometric data consumers are storing in wearables, wireless scales and glucometers.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
Patients are using their time in the waiting room to better prepare for upcoming discussions with their doctor. That makes it a good time for marketers to offer mobile-friendly info, researchers have found.
Shwen Gwee, the social media guru, has joined Digitas Health Lifebrands as VP of social strategy.
The two drugmakers inked a deal under which Sanofi holds rights to market the ED pill to consumers without a prescription, if the drug can make the switch.
The regulator's latest study will use eye-tracking tools.